Ruoji Zhou

Ruoji Zhou

Auto-generated profile, based on publicly available information

Ruoji Zhou

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine of University of California at Los Angeles, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2016 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
EBEster Borras
Ester Borras
FLF. Anthony San Lucas
F. Anthony San Lucas
KCKyle Chang
Kyle Chang
RZRuoji Zhou
Ruoji Zhou
GMGita Masand
Gita Masand
EVEduardo Vilar
Eduardo Vilar
The molecular basis of the adenoma-to-carcinoma transition has been deduced using comparative analysis of genetic alterations observed through the sequential steps of intestinal carcinogenesis. However, comprehensive genomic analyses of adenomas and at-risk mucosa are still lacking. Therefore, our aim was to characterize the genomic landscape of colonic at-risk mucosa and adenomas. We analyzed the mutation profile and copy number changes of 25 adenomas and adjacent mucosa from 12 familial adenomatous polyposis patients using whole-exome sequencing and validated allelic imbalances (AI) in 37 adenomas using SNP arrays. We assessed for evidence of clonality and performed estimations on the proportions of driver and passenger mutations using a systems biology approach. Adenomas had lower mutational rates than did colorectal cancers and showed recurrent alterations in known cancer driver genes (APC, KRAS, FBXW7, TCF7L2) and AIs in chromosomes 5, 7, and 13. Moreover, 80% of adenomas had somatic alterations in WNT pathway genes. Adenomas displayed evidence of multiclonality similar to stage I carcinomas. Strong correlations between mutational rate and patient age were observed in at-risk mucosa and adenomas. Our data indicate that at least 23% of somatic mutations are present in at-risk mucosa prior to adenoma initiation. The genomic profiles of at-risk mucosa and adenomas illustrate the evolution from normal tissue to carcinoma via greater resolution of molecular changes at the inflection point of premalignant lesions. Furthermore, substantial genomic variation exists in at-risk mucosa before adenoma formation, and deregulation of the WNT pathway is required to foster carcinogenesis. Cancer Prev Res; 9(6); 417–27. ©2016 AACR.

15 December 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
SCSheng Chen
Sheng Chen
YJYi-Zhou Jiang
Yi-Zhou Jiang
LHLiang Huang
Liang Huang
RZRuo-Ji Zhou
Ruo-Ji Zhou
KYKe-Da Yu
Ke-Da Yu
ZSZhi-Ming Shao
Zhi-Ming Shao
This study sought to investigate the prognostic value of the autophagy marker microtubule-associated protein chain 3B (LC3B) in patients with residual tumors after neoadjuvant chemotherapy (NCT) for locally advanced breast cancer (LABC). The expression of LC3B in residual breast cancer cells was assessed by immunohistochemistry in surgical specimens from 229 patients diagnosed with histologically proven invasive breast cancer. All patients underwent NCT followed by mastectomy and were considered nonpathologic complete responders (non-pCR) after a pathologic evaluation. The prognostic value of various clinicopathologic factors was evaluated. The LC3B density was similar between the peripheral and central area of the tumors (P = 0.328) but was significantly lower in the extratumoral area (P < 0.001 and P < 0.001, respectively). Furthermore, LC3B density, which correlated with Beclin-1 expression, Ki-67 index, and breast cancer subtype, served as an independent prognostic factor for both relapse-free survival (RFS; P = 0.012) and overall survival (OS; P = 0.008); the prognostic value of LC3B was most significant in triple-negative patients. Using a combination of LC3B expression and the status of residual involved lymph nodes, the patients were classified into four groups with different risks of relapse and death (P < 0.001 for RFS and P = 0.003 for OS). LC3B can be used as a prognostic marker in patients with non-pCR after NCT for breast cancer, which highlights the importance of autophagy in the biologic behavior of chemoresistant cancer cells. Furthermore, evaluating and targeting autophagy in the neoadjuvant setting may help prevent disease relapse in patients with non-pCR.

20 November 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HKHuensuk Kim
Huensuk Kim
SYSeungyeul Yoo
Seungyeul Yoo
RZRuoji Zhou
Ruoji Zhou
AXAn Xu
An Xu
JBJeffrey M. Bernitz
Jeffrey M. Bernitz
CSChristoph Schaniel
Christoph Schaniel
Significance: Li–Fraumeni syndrome is a rare disorder caused by germline TP53 mutations, predisposing patients to early-onset cancers, including osteosarcoma (OS). Here we demonstrate that strong expression of SFRP2, a reported WNT antagonist, in OS patient samples correlates with poor survival and that SFRP2 overexpression suppresses normal osteoblast differentiation, promotes OS features, and facilitates angiogenesis via autocrine and paracrine mechanisms in an induced pluripotent stem cell disease model. We show that these SFRP2-mediated phenotypes are canonical WNT/β-catenin independent and are mediated through induction of oncogenes such as FOXM1 and CYR61. We further demonstrate that inhibition of SFRP2, FOXM1, or CYR61 represses tumorigenesis. Our data suggest that inhibition of SFRP2 should be explored clinically as a strategy for treatment patients with p53 mutation-associated OS.

22 March 2012 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SCSheng Chen
Sheng Chen
CCCan-Ming Chen
Can-Ming Chen
KYKe-Da Yu
Ke-Da Yu
RZRuo-Ji Zhou
Ruo-Ji Zhou
ZSZhi-Ming Shao
Zhi-Ming Shao

25 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SCSheng Chen
Sheng Chen
CCCan-Ming Chen
Can-Ming Chen
YZYing Zhou
Ying Zhou
RZRuo-Ji Zhou
Ruo-Ji Zhou
KYKe-Da Yu
Ke-Da Yu
ZSZhi-Ming Shao
Zhi-Ming Shao
To evaluate the relationship between body mass index (BMI) and response to neoadjuvant chemotherapy (NCT) for breast cancer among Chinese women. A total of 307 eligible patients were assigned to receive four cycles of paclitaxel and carboplatin before standard surgery for breast cancer from 2007 to 2011 at Shanghai Cancer Hospital. The patients were categorized as obese, overweight, normal weight, or underweight based on BMI according to World Health Organization (WHO) criteria. Pathological complete response (pCR) was defined as no invasive cancer in the breast or axillary tissue. A logistic regression and the Chi-squared test were used for detecting the predictors of pCR and determining the relationship between BMI category and pCR rate in the subgroup analysis with respect to other variables. Categorical BMI, estrogen receptor (ER), and progesterone receptor (PR) status were independent predictors of pCR according to the multivariate analysis. Patients with BMI≥25 were less likely to achieve a pCR to NCT compared with patients with BMI<25 (Odds ratio: 0.454, p = 0.033, multivariate analysis). In the subgroup analysis, the predictive value of BMI for pCR to NCT was significantly shown in post-menopausal patients (p = 0.004) and hormonal receptor status-negative patients (p = 0.038). The incidence of treatment-induced toxicity was similar among the different BMI categories. Higher BMI was associated with worse pCR to NCT. Further approaches to investigating the mechanism of this influence of BMI on treatment response and a more appropriate schedule for calculating NCT dose for high-BMI-patients should be considered.

1 October 2017 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
RZRuoji Zhou
Ruoji Zhou
AXAn Xu
An Xu
JGJulian Gingold
Julian Gingold
LSLouise C. Strong
Louise C. Strong
RZRUIYING ZHAO
RUIYING ZHAO
Dung-Fang LeeDung-Fang Lee
Dung-Fang Lee